Efficacy of Intravenous Immunoglobulin in Management of Rh and ABO Incompatibility Disease
Status:
Unknown status
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
hemolytic disease of newborn is an important cause of hyperbilirubinemia with significant
morbidity and mortality in neonatal period. intravenous immunoglobulin has widely used in
management of hemolytic disease of new born